Introduction {#Sec1}
============

Type 2 diabetes is a common complex disease characterised by deficient insulin secretion and decreased insulin sensitivity. In 2010, 285 million people worldwide were affected by type 2 diabetes \[[@CR1]\], with 60% of them located in Asia \[[@CR2], [@CR3]\]. China now has the largest number of patients with diabetes in the world, with an estimated 92 million affected individuals, and an additional 150 million with impaired glucose tolerance \[[@CR4]\].

To identify common type 2 diabetes susceptibility variants, large-scale genome-wide association studies (GWAS) have been conducted in white individuals, yielding more than 60 genetic loci to date \[[@CR5], [@CR6]\]. Although many of these regions have been successfully replicated in Asian populations \[[@CR7]--[@CR11]\], discrepancies in allelic frequencies and effect sizes have demonstrated that interethnic differences exist. GWAS conducted in Japanese individuals \[[@CR12], [@CR13]\], as well as meta-analyses of GWAS in South Asian \[[@CR14]\] and East Asian \[[@CR15]\] groups, have revealed additional variants not detected in GWAS with white individuals, with several signals, including *KCNQ1*, later replicated in many populations \[[@CR12], [@CR13]\]. Previous GWAS in Chinese suggested several loci but lacked large-scale replication \[[@CR16]--[@CR18]\].

We therefore conducted this study to identify new type 2 diabetes susceptibility loci in Southern Han Chinese individuals. We performed a meta-analysis of three GWAS comprising 684 patients with type 2 diabetes and 955 controls, and analysed 2.9 million (genotyped and imputed) single-nucleotide polymorphisms (SNPs) in an additive model. Putatively associated SNPs (*p* \< 1 × 10^−5^) were genotyped de novo in two independent Southern Han Chinese cohorts (10,383 cases and 6,974 controls), and SNPs reaching a genome-wide significance of *p* \< 5 × 10^−8^ were replicated in silico in five East Asian and three non-East Asian populations for a total of 31,541 cases and 60,344 controls.

Methods {#Sec2}
=======

Participants {#d30e1277}
------------

In the first-stage discovery cohort (stage 1), we performed genome-wide scanning in three different case--control samples: 198 Hong Kong Chinese individuals (99 patients with type 2 diabetes and 99 healthy controls) in Hong Kong GWAS 1, 1,047 Hong Kong Chinese individuals (388 with type 2 diabetes and 659 controls) in Hong Kong GWAS 2 and 394 Shanghai Chinese (197 patients with type 2 diabetes and 197 normal controls) in the Shanghai GWAS. Individuals included in the stage 2 replication included 5,366 with type 2 diabetes and 2,474 controls from Hong Kong, and 4,035 cases and 3,964 controls from Shanghai. We also included 325 cases and 368 controls from 178 Hong Kong families, as well as 657 cases and 168 controls from 248 Shanghai families.

Case--control samples for in silico replication in stage 3 were taken from several published type 2 diabetes GWAS in East Asian individuals. These included the Korea Association Resource Study \[[@CR19]\], the Singapore Chinese from the Singapore Diabetes Cohort Study and the Singapore Prospective Study Program \[[@CR20]\], the BioBank Japan Study \[[@CR13]\] and a Han Chinese Study \[[@CR21]\]. For stage 4 in silico replication in other populations, Malaysian participants from the Singapore Malay Eye Study, Indian participants from the Singapore Indian Eye Study \[[@CR20]\] and participants of European descent in the Diabetes Genetics Replication And Meta-analysis (DIAGRAM) Consortium \[[@CR6]\] were included.

The study design, type 2 diabetes diagnostic criteria and clinical evaluation used in each study are described in the electronic supplementary material ([ESM](#MOESM1){ref-type="media"}) Methods. The clinical characteristics of the study individuals are described in Table [1](#Tab1){ref-type="table"}. Each study obtained approval from the appropriate institutional review boards of the respective institutions, and written informed consent was obtained from all participants. The overall study design is depicted in Fig. [1](#Fig1){ref-type="fig"}.Table 1Clinical characteristics of the participantsStudyCohort*N* (male %)Age (years)AAD (year)Diabetes duration (years)BMI (kg/m^2^)FPG (mmol/l)Stage 1 (genome scan)HK1Control99 (36.4)37.3 ± 10.2----20.8 ± 2.04.7 ± 0.4T2D patient99 (40.4)40.6 ± 8.831.8 ± 7.78.0 ± 8.330.9 ± 4.4--HK2Diseased control659 (48.7)37.1 ± 17.0----23.3 ± 3.7--T2D patient388 (49.5)60.6 ± 10.851.1 ± 12.19.5 ± 7.025.0 ± 3.8--SHControl197 (50.8)66.4 ± 10.1----20.6 ± 1.74.8 ± 0.4T2D patient197 (57.9)41.6 ± 10.434.5 ± 4.87.3 ± 8.523.8 ± 4.1--Stage 2 (de novo replication in Chinese)HK1Adolescent control985 (44.2)15.5 ± 1.9----22.7 ± 5.44.9 ± 0.4Adults control513 (47.0)42.0 ± 10.4----19.9 ± 3.54.7 ± 0.3Elderly control976 (51.4)72.3 ± 5.3----23.2 ± 3.2--T2D patient5,366 (45.1)56.7 ± 13.448.8 ± 14.96.6 ± 6.924.6 ± 5.3--SH1Control3,964 (37.6)51.3 ± 13.5----23.6 ± 3.25.0 ± 0.5T2D patient4,035 (52.0)61.2 ± 12.154.2 ± 11.37.2 ± 6.924.5 ± 3.5--HK Family 2Control368 (41.0)37.0 ± 13.6----24.0 ± 4.14.9 ± 0.4T2D patient325 (40.6)48.0 ± 14.441.7 ± 13.16.3 ± 7.625.9 ± 4.4--SH Family 2Control168 (51.2)62.8 ± 11.2----23.7 ± 3.54.8 ± 0.6T2D patient657 (43.7)54.6 ± 15.650.0 ± 14.24.9 ± 7.323.9 ± 3.5--Stage 3 (in silico replication in East Asians)JapaneseControl3,023 (54.5)51.9 ± 15.2----22.4 ± 3.7--T2D patient4,465 (68.0)65.8 ± 10.056.5 ± 11.49.4 ± 8.424.1 ± 3.8--Korean 1Control2,943 (46.0)51.1 ± 8.6----24.1 ± 3.04.5 + 0.4T2D patient1,042 (51.7)56.4 ± 8.6----25.5 ± 3.37.0 ± 2.6Korean 2Control1,305 (54.5)65.2 ± 2.6----23.9 ± 3.05.0 ± 0.5T2D patient1,183 (46.5)58.6 ± 7.1----25.2 ± 3.47.4 ± 2.7Singapore Chinese 1Control1,006 (21.6)47.7 ± 11.1----22.3 ± 3.74.7 ± 0.4T2D patient1,082 (37.2)65.1 ± 9.755.7 ± 12.0--25.3 ± 3.9--Singapore Chinese 2Control939 (63.8)46.7 ± 10.2----22.8 ± 3.44.7 ± 0.5T2D patient928 (64.9)63.7 ± 10.852.2 ± 14.4--25.4 ± 3.8--ChineseControl1,839 (43.7)54.1 ± 9.2----24.00 ± 3.185.04 ± 0.35T2D patient1,873 (46.0)58.6 ± 8.4----25.00 ± 3.248.43 ± 2.90Stage 4 (in silico replication in non-East Asians)Singapore MalaysianControl1,240 (52.0)56.9 ± 11.4----25.1 ± 4.8--T2D patient794 (51.0)62.3 ± 9.9054.4 ± 11.2--27.8 ± 4.9--Singapore IndiansControl1,169 (48.4)55.7 ± 9.7----25.3 ± 4.4--T2D patient977 (54.4)60.7 ± 9.951.4 ± 10.6--27.1 ± 5.1--DIAGRAM+Control38,987 (--)----------T2D patient8,130 (--)----------Data are shown as *N*, percentage or mean ± SDT2D, type 2 diabetesFig. 1Summary of study design. CHB, Han Chinese in Beijing, China; JPT, Japanese in Tokyo, Japan

Quality control on the samples for the GWAS {#d30e2194}
-------------------------------------------

In our study, individuals were excluded from further analysis if: (1) duplicate samples existed; (2) the sex identified from the X chromosome was discordant with the sex obtained from the medical records; (3) the genotype call rate yield was \<98%. We detected possible familial relationship using estimates of identity by descent derived from pair-wise analyses of independence (*r*^2^ ≈ 0) and quality SNPs. Individuals with evidence for relatedness were excluded ($\documentclass[12pt]{minimal}
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                \begin{document}$$ \widehat{{{p_1}}} > 0.05 $$\end{document}$). ESM Table [1](#MOESM11){ref-type="media"} shows the quality control for the participants in stage 1.

To discriminate individuals from different geographical origins, we conducted multidimensional scaling analysis using the genotype data obtained from unrelated individuals in the present study and the other 11 populations studied by the HapMap project (ESM Fig. [1](#MOESM3){ref-type="media"}). Individuals were excluded from subsequent analyses if they lay between clusters.

Genotyping and quality control on the SNP data {#d30e2218}
----------------------------------------------

Individuals for the stage 1, 3 and 4 analyses were genotyped using high-density SNP typing arrays that covered the entire genome. Only autosomal SNPs were included. Quality checks for SNPs were performed in the case and control samples separately, although the same criteria were applied to each. SNPs were excluded from further analysis if: (1) *p* \< 1 × 10^−4^ for Hardy--Weinberg equilibrium (HWE); (2) minor allele frequency (MAF) was \<1%; (3) call rate was \<95%; in particular, SNPs with MAF ≥ 1% but ≤5% were excluded if their call rate was \<99%; or (4) the SNPs showed a significant difference in MAF (*p* \< 1 × 10^−4^) between the Hong Kong control cohorts with other conditions (450 with epilepsy, 110 with eczema and 99 non-hypertensive individuals). Only SNPs that passed the quality control criteria for both cases and controls were used for further analysis. ESM Table [2](#MOESM12){ref-type="media"} shows the quality control of the genotyping results in stage 1. We imputed genotypes for autosomal SNPs according to the 1000 Genomes reference panel. See the [ESM Methods](#MOESM1){ref-type="media"} for further details.

For de novo replication in stage 2, all selected SNPs were genotyped in the Hong Kong and Shanghai case--control samples by a primer extension of multiplex products with detection by Matrix-assisted laser desorption ionisation-time of flight mass spectroscopy using a MassARRAY platform (Sequenom; San Diego, CA, USA). Family samples were genotyped using TaqMan SNP Genotyping Assays (Applied Biosystems, Foster City, CA, USA) or by direct sequencing.

Statistical analysis {#d30e2244}
--------------------

All statistical analyses were performed using PLINK version 1.07 (<http://pngu.mgh.harvard.edu/~purcell/plink/>) \[[@CR22]\], SAS version 9.1 (SAS Institute, Cary, NC, USA) or SPSS for Windows version 18 (SPSS, Chicago, IL, USA), unless specified otherwise. Haploview version 4.1 was used to generate pair-wise linkage disequilibrium (LD) measures (*r*^2^).

To test for an association with type 2 diabetes, we applied logistic regression under an additive genetic model using the MACH2DAT software ([www.sph.umich.edu/csg/abecasis/MACH/download/](http://www.sph.umich.edu/csg/abecasis/MACH/download/)) \[[@CR23]\] adjusted for sex and age according to situations in the individual studies.

To combine the type 2 diabetes association results in stage 1, GWAMA software ([www.well.ox.ac.uk/gwama/](http://www.well.ox.ac.uk/gwama/)) \[[@CR24]\] was used to calculate the combined estimates of the ORs (95% CIs) from multiple groups by weighting the natural log-transformed ORs of each study using the inverse of their variance under the random effect model \[[@CR25]\]. By using the random effect model, we excluded SNPs with some degree of heterogeneity between studies, which helped to attenuate the number of false-positive findings in this study. Cochran's *Q* statistic (*p* \< 0.05) and *I*^2^ index were used to assess the heterogeneity of ORs between studies.

The most strongly associated SNPs were prioritised for follow-up in stage 2 based on the meta-analysis results from stage 1. SNPs located within a previously reported type 2 diabetes locus were excluded. We finally considered 13 top and proxy SNPs from four distinct loci available in all three GWAS with (1) a meta-analysis *p* \< 1 × 10^−5^; (2) a heterogeneity test *p* \> 0.05; (3) the same direction of risk allele across all three GWAS; (4) a common allele frequency (MAF ≥ 0.1). For SNPs imputed across all three studies, we selected the most significant SNP associated with type 2 diabetes. ESM Tables [3](#MOESM13){ref-type="media"} and [4](#MOESM14){ref-type="media"} describe the details of the selected SNPs and the quality control for the genotyping results in stage 2.

In the replication stage, genotype frequencies were compared between cases and controls using logistic regression under an additive genetic model. In the family studies, alternating logistic regressions (ALR) implemented in the SAS procedure GENMOD was used to test for the association between type 2 diabetes and SNPs under an additive genetic model adjusted for age and sex. ALR is one type of generalised estimating equation applicable to binary outcomes that can handle correlated data (e.g. familial correlation). ORs (95% CIs) are presented in both analyses. Meta-analyses and heterogeneity tests were conducted as described previously to combine estimates of the ORs (95% CIs) from multiple case--control and family groups under the fixed effect model. Multiple testing in the combined analysis of the case--control study were controlled by Bonferroni correction, and *p* \< 4.5 × 10^−3^ (0.05 divided by 11 SNPs in the stage 2 replication studies) was used as the threshold for filtering SNPs genotyped in the family studies.

Continuous data are presented as mean ± SD or geometric mean (95% CI). Traits were log~*e*~-transformed due to skewed distributions. Associations between genotypes and quantitative traits were tested by linear regression (adjusted for sex, age and/or BMI) in each healthy control cohort, as were associations for age at diagnosis (AAD) among patients with type 2 diabetes (adjusted for sex, BMI and/or HbA~1c~). Meta-analyses implemented by GWAMA were applied to combine effect size (*β* ± SE) from multiple groups under the fixed effect model.

We performed bioinformatics and *cis*-expression quantitative trait loci (eQTL) analysis for functional implication of the identified SNP. See the [ESM Methods](#MOESM1){ref-type="media"} for additional information on methods, including adjustment for genomic control and the gene network analysis.

Results {#Sec3}
=======

Meta-analysis of patients with Chinese ancestry {#d30e2345}
-----------------------------------------------

A summary of the study design and the clinical characteristics of the participants in all stages are shown in Fig. [1](#Fig1){ref-type="fig"} and Table [1](#Tab1){ref-type="table"}. In stage 1, we genotyped 684 patients with type 2 diabetes and 955 controls. We did not detect any population stratification between case and control individuals in multidimensional scaling analysis for all GWAS (ESM Fig. [2](#MOESM4){ref-type="media"}). Meta-analysis was implemented to combine the individual association results for 2,925,090 imputed and genotyped SNPs (under additive genetic models) available in all three GWAS using the inverse-variance approach for random effect models.

In the stage 1 meta-analysis of three Chinese GWAS, 44 SNPs within five loci were prioritised for follow-up (Fig. [2](#Fig2){ref-type="fig"} and ESM Table [5](#MOESM15){ref-type="media"}). We did not observe a substantial change in the stage 1 results after adjusting either for λs (1.01--1.04 in individual cohorts) or the first principal component in the meta-analysis, reflecting that the results were not likely to be due to population stratification (ESM Fig. [3](#MOESM5){ref-type="media"} and ESM Table [6](#MOESM16){ref-type="media"}).Fig. 2Manhattan plot of combined genome-wide association results from the Hong Kong 1, Hong Kong 2 and Shanghai studies based on the random effect models. The *y*-axis represents the −log~10~*p* value, and the *x*-axis represents the 2,925,090 analysed SNPs. The dashed horizontal line indicates the threshold of significance *p* \< 1 × 10^−5^. There are 44 points with *p* \< 1 × 10^−5^, and the arrow and labels localise the susceptibility loci to type 2 diabetes uncovered in the present study

Of the five loci identified in stage 1, *CDKN2A/B* has previously been reported to be strongly associated with type 2 diabetes. In line with our previous findings, two SNPs in *CDKN2A/B* showing strong signals for type 2 diabetes in the present study were in high LD (*r*^2^ ≈ 0.8) with rs10811661, which is well-replicated in most populations. After eliminating the signal of *CDKN2A/B* and redundant markers, we took forward 13 top and proxy SNPs among the remaining 42 SNPs in four regions to stage 2, de novo replication, in two independent Chinese case--control cohorts (ESM Table [3](#MOESM13){ref-type="media"}). We successfully obtained genotypes for 11 SNPs in Hong Kong replication 1 cohort with 5,366 cases and 2,474 controls, and Shanghai replication 1 cohort with 4,035 cases and 3,964 controls to proceed for subsequent analysis (ESM Table [4](#MOESM14){ref-type="media"}). Of these, rs10229583 and rs2737250, located on chromosomes 7 and 8, respectively, gave *p* ≤ 4.5 × 10^−3^ (threshold of significance after Bonferroni correction) with the same directions of association as the original signals (Table [2](#Tab2){ref-type="table"}). These two SNPs were genotyped in 1,518 additional samples from 426 families of Han Chinese descent (325 cases and 368 controls from 178 Hong Kong families, and 657 cases and 168 controls from 248 Shanghai families). Although we did not detect a significant association in either family study using ALR, all were in the concordant direction for rs10229583 (ESM Table [7](#MOESM17){ref-type="media"}). Taken together, the overall observed association for type 2 diabetes with rs10229583 by combining all studies from Chinese ancestry in stages 1 and 2 yielded an OR (95% CI) of 1.18 (1.11, 1.25) with a corresponding *p* = 2.6 × 10^−8^ (Table [3](#Tab3){ref-type="table"}). For another variant taken to genotyping in family samples, rs2737250, meta-analysis of GWAS and de novo genotyping in the Hong Kong and Shanghai case--control samples revealed OR 1.10 (1.05, 1.15) with a corresponding *p* = 7.05 × 10^−5^ using a fixed effect model (*p* for heterogeneity test = 0.0012, *I*^2^ = 0.852), with OR 1.16 (1.01, 1.33), *p* = 0.0299 by random effect model. However, genotyping of the variant in the Hong Kong and Shanghai family samples suggested an association in the opposite direction (ESM Table [7](#MOESM17){ref-type="media"}).Table 2Association results for type 2 diabetes (T2D) with 11 top and proxy SNPs in de novo replication stage in Chinese populationsHong Kong replication 1 (5,366 T2D vs 2,474 controls)Shanghai replication 1 (4,035 T2D vs 3,964 controls)CombinedSNPChromosomeNearest gene(s)Position (B36)Minor/major alleleCase MAFControl MAFOR (95% CI)*p*~additive~Case MAFControl MAFOR (95% CI)*p*~additive~OR (95% CI)*p*~meta~ (uncorrected)*p*~het~*I*^2^rs102295837*PAX4*127034139A/G0.8470.831.14 (1.03, 1.23)0.00770.8460.8251.16 (1.08, 1.27)3.7 × 10^−4^1.15 (1.08, 1.22)1.0 × 10^−5^0.64060.000rs27219608*TRPS1*116725904T/C0.6570.6441.05 (0.98, 1.14)0.15660.6550.6381.08 (1.01, 1.15)0.02771.06 (1.02, 1.12)0.00950.70670.000rs27372508*TRPS1*116731048G/A0.6310.621.05 (0.98, 1.12)0.18070.6410.6211.09 (1.02, 1.16)0.00901.08 (1.02, 1.12)0.00450.45820.000rs385815810*COL13A1*71310056C/T0.5160.5210.98 (0.92, 1.05)0.60000.5690.5611.03 (0.97, 1.10)0.32111.01 (0.96, 1.05)0.74080.30260.506rs239527210*COL13A1*71310261A/G0.5310.5340.99 (0.93, 1.06)0.76800.5940.5841.04 (0.97, 1.11)0.23121.02 (0.97, 1.06)0.45890.30270.364rs5770346510*COL13A1*71311074T/C0.6540.6620.96 (0.89, 1.04)0.34630.6670.6561.05 (0.98, 1.12)0.15021.01 (0.96, 1.06)0.64670.09760.765rs1106544112*P2RX7*120045354C/T0.7280.7241.02 (0.94, 1.11)0.62240.7280.7330.97 (0.91, 1.04)0.43120.99 (0.94, 1.05)0.77560.37480.000rs68420112*P2RX7*120054726A/G0.730.7261.02 (0.94, 1.10)0.59160.7350.7390.98 (0.91, 1.05)0.56091.00 (0.94, 1.05)0.94620.43320.000rs1106545012*P2RX7*120064040A/C0.6820.6880.97 (0.90, 1.05)0.49950.7020.7070.98 (0.92, 1.05)0.55200.98 (0.93, 1.03)0.36990.91110.000rs20829012*P2RX7*120078439T/C0.6120.6091.01 (0.94, 1.09)0.70860.6430.6450.99 (0.93, 1.06)0.79501.00 (0.95, 1.05)0.96050.64720.000rs1084985112*P2RX7*120081027G/A0.7270.721.03 (0.95, 1.12)0.40790.7370.7410.98 (0.91, 1.05)0.52371.00 (0.95, 1.05)0.93080.30020.068Nearest Entrez genes within 250 kb*p*, *p*~meta~ and *p*~het~ represent *p* values from logistic regression without any adjustment under the additive genetic model, meta-analysis under a fixed effect model (uncorrected for multiple testing) and test of heterogeneity, respectivelyORs are reported with respect to the minor alleleTable 3Association results for rs10229583 and type 2 diabetes (T2D)*N*Risk allele frequenciesStageCohortAdjustmentT2DControlT2DControlOR (95% CI)*p*~additive~ (uncorrected GC)*p*~het~*I*^2^1. DiscoveryHong Kong GWAS 1Sex and age99990.8790.8181.48 (0.85, 2.59)0.1645Hong Kong GWAS 2Sex and age3886590.8570.8201.56 (1.14, 2.13)0.0055Shanghai GWASNone1971970.8730.7771.92 (1.32, 2.79)5.0 × 10^−4^Meta-analysis of GWAS6849551.66 (1.33, 2.07)7.7 × 10^−6^0.64550.0002. De novo replications in Hong Kong and ShanghaiHong Kong replication 1None5,3662,4740.8470.8311.13 (1.03, 1.24)7.7 × 10^−3^Shanghai replication 1None4,0353,9640.8460.8251.17 (1.07, 1.27)3.7 × 10^−4^Hong Kong family replication 2Sex and age3253680.8720.8561.22 (0.85, 1.74)0.2817Shanghai family replication 2Sex and age6571680.8240.8131.09 (0.80, 1.49)0.5757Replication in Chinese10,3836,9741.15 (1.08, 1.22)1.0 × 10^−5^0.64060.000Meta-analysis of Chinese11,0677,9291.18 (1.11, 1.25)2.6 × 10^−8^0.08390.5963. In silico replications in East AsiansJapanese replicationNone4,4653,0230.8920.8811.11 (1.01, 1.23)0.0379Korean replication 1None1,0422,9430.8940.8781.17 (0.99, 1.38)0.0577Korean replication 2None1,1831,3050.8410.8440.98 (0.84, 1.15)0.8101Singapore Chinese replication 1None1,0821,0060.8320.8191.07 (0.95, 1.20)0.2728Singapore Chinese replication 2None9289390.8330.816Chinese replicationFirst 2 PCs1,8731,8390.83960.81671.17 (1.04, 1.32)0.01091Replication in other East Asian10,57311,0551.10 (1.04, 1.17)6.0 × 10^−4^0.67670.000Meta-analysis of East Asian21,64018,9841.14 (1.09, 1.19)2.3 × 10^−10^0.59390.0004. In silico replications in South Asians and EuropeansSingapore Malaysian replicationNone7941,2040.7980.8040.97 (0.83, 1.14)0.7185Singapore Indian replicationNone9771,1690.6470.6820.86 (0.76, 0.98)0.0276DIAGRAMNone8,13038,987----1.06 (1.02, 1.12)8.6 × 10^−3^Replication in non-East Asian9,90141,3601.03 (0.99, 1.08)0.11560.00420.878ORs and 95% CIs were reported with respect to the T2D-related risk alleles (G)*p*~het~ refers to the *p* value obtained from the heterogeneity testGC, genomic control; PC, principal components

Meta-analysis in East Asian and other populations {#d30e3861}
-------------------------------------------------

To further validate the association of rs10229583 with type 2 diabetes, we conducted in silico replication of rs10229583 in five East Asian GWAS (one Japanese, two Korean, one Singapore Chinese and one Han Chinese study), and three non-East Asian GWAS (Singapore Indian, Singapore Malaysian and the DIAGRAM Consortium). Meta-analysis for the East Asian populations (*p* = 2.3 × 10^−10^) gave an OR (95% CI) of 1.14 (1.09, 1.19). Among non-East Asian populations, we observed replication of the association in participants of European descent from the DIAGRAM Consortium (*p* = 8.6 × 10^−3^), with OR 1.06 and (95% CI 1.02, 1.12) (Table [3](#Tab3){ref-type="table"} and Figs [3](#Fig3){ref-type="fig"} and [4](#Fig4){ref-type="fig"}).Fig. 3Regional plots for the identified variant rs10229583, including results for both genotyped and imputed SNPs in the Chinese population. The purple circle and diamond represent the sentinel SNP in meta-analysis of three GWAS in the stage 1 and the East Asian meta-analysis in stages 1 + 2 + 3, respectively. Other SNPs are coloured according to their level of LD, which is measured by *r*^2^, with the sentinel SNP. The recombination rates estimated from the 1000 Genomes project JPT + CHB data are shown. CHB, Han Chinese in Beijing, China; JPT, Japanese in Tokyo, JapanFig. 4Forest plot for meta-analysis of the association between type 2 diabetes and rs10229583 for all populations in the present study. ORs and 95% CIs were reported with respect to the type 2 diabetes-related risk alleles (G)

Impact of rs10229583 on clinical traits and course of disease {#d30e3911}
-------------------------------------------------------------

We next investigated the associations of rs10229583 with the AAD of type 2 diabetes and quantitative metabolic traits related to type 2 diabetes. Among all the patients with type 2 diabetes, individuals who carried the common, type 2 diabetes risk allele (G) were concordantly and significantly younger at the time of diagnosis in both Hong Kong and Shanghai, and the meta-analysis showed that presence of the risk variant had a significant association with younger AAD (*p* = 2.3 × 10^−4^, *β*~unadjusted~ ± SE =−0.90 ± 0.24), which remained unchanged following adjustment for sex and BMI (ESM Table [8](#MOESM18){ref-type="media"}). We also observed a nominal association of the G-alleles of rs10229583 with beta cell function as assessed by HOMA-B (*β*~unadjusted~ ± SE =−0.06 ± 0.03, *p* = 0.0221) in healthy Hong Kong adolescents, a reduced Stumvoll Index (*β*~unadjusted~ ± SE = 0.03 ± 0.01, *p* = 0.0303) and increased fasting plasma glucose (FPG) level (*β*~unadjusted~ ± SE = 0.03 ± 0.01, *p* = 0.0460) in healthy Shanghai adults (Fig. [5](#Fig5){ref-type="fig"}).Fig. 5Associations of the risk variant (G allele) of rs10229583 with measures of insulin secretion in Chinese controls. (**a**) Association with reduced HOMA-B in a Hong Kong Chinese adolescent cohort (*p* = 0.0221). (**b**) Association with a reduced Stumvoll Index of beta cell function in healthy Shanghai controls (*p* = 0.0303). (**c**) Association of the risk variant with higher FPG in healthy Shanghai controls (*p* = 0.0460). Data are expressed as mean (for FPG) or geometric mean (for HOMA-B and Stumvoll Index). SDs or 95% CIs are expressed as error bars. The number of individuals analysed for each genotype is shown in parentheses under each column

Functional implication of the identified locus rs10229583 {#d30e3987}
---------------------------------------------------------

In order to evaluate the functional implication of our identified variant, we performed an extensive bioinformatics analysis. Consistent with its observed effect on pancreatic beta cell function, the gene region of our locus has been identified as one of the islet-selective clusters of open regulatory elements using a formaldehyde-assisted isolation of regulatory elements coupled with high-throughput sequencing in human pancreatic islets \[[@CR26]\]. In addition, the variant and its tagging SNPs lie within an area near *PAX4* and *SND1*, which is enriched with DNase I hypersensitive sites, histone H3 lysine modifications and CCCTC factor binding in human islets (ESM Fig. [4](#MOESM6){ref-type="media"}) \[[@CR27]\].

We next investigated the relationship of rs10229583 with eQTLs in adipose tissue and other tissues in available datasets. The variant rs1440971, a proxy of our associated SNP (MAF ∼ 0.1, *r*^2^ = 0.8 and D\' = 1, to rs10229583), was significantly associated with the level of expression of *GRM8*, *ARF5* and *PAX4* in lymphoblastoid cells in the GenCord Project, although this did not correlate with the eQTL peak (ESM Fig. [5](#MOESM7){ref-type="media"} and ESM Table [9](#MOESM19){ref-type="media"}) \[[@CR28]\]. Analysis of all eQTLs associated with rs10229583, or its close proxy, rs1440971, was performed using data from the Multiple Tissue Human Expression Resource (MuTHER) Consortium \[[@CR29]\]. Of note, eQTL data were only available for *PAX4* in adipose tissue, but not lymphoblastoid cell lines (LCLs) or skin, for which no expression data were available from MuTHER. There was a nominal association (*p* \< 0.05) between the variant and expression of *C7orf54* and *ARF5* in LCLs, and *C7orf68* in adipose tissue (ESM Table [10](#MOESM20){ref-type="media"}). The *r*^2^ between the GWAS SNP and the peak eQTL SNPs ranged between 0.56 and 1.

Complex diseases such as type 2 diabetes are caused by a combination of alterations, and each genomic perturbation or alteration can potentially impact on thousands of genes \[[@CR30], [@CR31]\]. Nevertheless, functionally important genes often organise into the same pathway of functional grouping. Therefore, we can overlay the alterations on a gene network that was built using highly confident gene--gene relationships (ESM Fig. [6](#MOESM8){ref-type="media"}) \[[@CR32]\]. We identified interactions between these genes, with additional interaction with other key pancreatic transcription factors such as *NEUGRO3* (ESM Fig. [6](#MOESM8){ref-type="media"}). Taken together, we speculate that *ARF5*, *GCC1*, *SND1* and *PAX4* may function together with *NEUGRO3* in the same network for pancreatic islet development.

Heterogeneity of effect in Chinese vs other ethnic groups {#d30e4096}
---------------------------------------------------------

To investigate why the novel loci identified in the present study had not been detected in previous GWAS performed in other populations, we examined the heterogeneity of effect between East Asians and Europeans. There was no evidence of heterogeneity of effect between Chinese, Korean and Japanese populations, but significant heterogeneity of effect was seen between Han Chinese and individuals of European descent in the DIAGRAM Consortium, as well as between Chinese, Malaysians and Indians (ESM Table [11](#MOESM21){ref-type="media"}).

To test for the variation of LD structure between Chinese and other populations, we implemented the targeted varLD approach to examine the pattern of *r*^2^ between every pair of SNPs within the 100 kb region centred on our index SNP rs10229583. ([www.statgen.nus.edu.sg/\~SGVP/software/varld.html](http://www.statgen.nus.edu.sg/~SGVP/software/varld.html)) \[[@CR33]\]. This region shows highly significant evidence of LD variation between Chinese, European (Monte Carlo \[MC\] *p* = 0.0018), and African (MC *p* = 0.0003) individuals, but nominal evidence of variations between Chinese and Japanese (MC *p* = 0.0107) (ESM Table [12](#MOESM22){ref-type="media"} and ESM Figs [7](#MOESM9){ref-type="media"} and [8](#MOESM10){ref-type="media"}). We also observed discrepancies in allele frequency of rs10229583 between East Asians, Europeans and Africans (ESM Table [12](#MOESM22){ref-type="media"}).

Discussion {#Sec4}
==========

This study reports a meta-analysis of GWAS for type 2 diabetes in a Chinese population, and has identified a novel diabetes-associated locus. Furthermore, we replicated the association in additional East Asian samples, and found an association in samples of European descent. In addition to the multiethnic samples used in our study, our study also benefits from a detailed phenotyping of the Chinese samples, which allowed additional analyses of the effect of the risk variant on clinical traits and the course of disease to be carried out.

Type 2 diabetes in Asians is characterised by an earlier AAD, strong family history and evidence of impaired beta cell function \[[@CR2], [@CR3]\]. In a recent nationwide study conducted in China, the prevalence of diabetes was 3.2% among persons aged 20--39 years, and 11.5% among adults aged 40--59 \[[@CR4]\]. The risk variant we identified, rs10229583, was associated with earlier AAD in both the Hong Kong and Shanghai samples, highlighting its potential contribution to young-onset diabetes in the Chinese population. Healthy adults and adolescents who carry the risk variant were found to have elevated fasting glucose and impaired beta cell function, respectively.

The novel locus for type 2 diabetes we identified, rs10229583, is located downstream of the *ARF5* and *PAX4* genes in 7q32, and upstream of *SND1*. *PAX4*, which is a member of the paired box family of transcription factors, plays a critical role in pancreatic beta cell formation during fetal development \[[@CR34], [@CR35]\] and is therefore a very strong candidate for the implicated gene. The gene region lies within an area of islet-specific cluster of open chromatin sites and may therefore act in *cis* with local chromatin and regulatory changes \[[@CR25]\]. *PAX4* is expressed in early pancreatic endocrine cells, but expression is later restricted to beta cells and it is not expressed in mature pancreas \[[@CR36]\]. In pancreatic endocrine cells, *PAX4* represses ghrelin and glucagon expression, and can induce the expression of *PDX1*, a key transcription factor for islet development \[[@CR37]\]. Targeted disruption of *PAX4* in mice was found to lead to reduced beta cell mass at birth \[[@CR37]\].

Several human studies have implicated *PAX4* in the pathogenesis of diabetes \[[@CR38], [@CR39]\]. In one report, a missense mutation (R121W) was identified in six heterozygous patients and one homozygous patient out of 200 unrelated Japanese patients with type 2 diabetes \[[@CR39]\]. For example, Japanese patients carrying *PAX4* mutations have severe defects in first-phase insulin secretion \[[@CR40]\]. Mutations in *PAX4* may lead to rare monogenic forms of young-onset diabetes \[[@CR41]\]. Common variants in several other MODY genes, namely, *HNF4a*, *HNF1a* and *TCF2*, have been identified as susceptibility loci for type 2 diabetes \[[@CR42]\].

Our finding is consistent with other studies that have highlighted the important role of genes implicated in pancreatic development in the pathogenesis of type 2 diabetes. In a previous study, a risk variant at *HNF4a* has been found to be associated with increased risk of type 2 diabetes, and carriers of the risk allele have impaired beta cell function \[[@CR43]\]. The MAF of the R121W *PAX4* mutation was 1% in Asians, and the mutation is in low LD with rs10229583. It is possible that both rare mutations and common variation within the same gene confer risk towards type 2 diabetes independently. The common variant we identified, rs10229583, may be associated with altered gene expression, while the other rare non-synonymous mutations lead to impaired gene function. For example, while common non-coding variants in *MTNR1B* increase type 2 diabetes risk with a modest effect, large-scale resequencing has identified rare loss-of-function *MTNR1B* variants that significantly contribute towards type 2 diabetes risk \[[@CR44]\]. Some regulatory elements harbouring type 2 diabetes-associated loci have recently been found to exhibit allele-specific differences in activity, providing evidence supporting the functional role of non-coding common variants identified through GWAS \[[@CR26], [@CR27]\].

The recent East Asian meta-analysis comprising eight type 2 diabetes GWAS identified a locus on chromosome 7 near *GRIP* and *GCC1*-*PAX4* to be associated with type 2 diabetes. The protein encoded by *GCC1* may play a role in transmembrane transport \[[@CR45]\]. The variant identified from the East Asian study, rs6467136, appears to be independent of our signal, with *r*^2^ = 0.044 in our Chinese samples (ESM Fig. [8](#MOESM10){ref-type="media"}). Furthermore, we found no change in the effect size of rs10229583 after conditioning on rs6467136 (OR \[95% CI\] = 1.20 \[1.11, 1.29\], *p* = 4.6 × 10^−6^ vs OR \[95% CI\] = 1.19 \[1.10, 1.29), *p* = 1.6 × 10^−5^, before and after the conditional analysis in 9,886 Chinese samples). Likewise, rs6467136 had little change in effect after conditioning on rs10229583 (OR \[95% CI\] = 1.09 \[1.02, 1.17\], *p* = 0.0125 before; OR \[95% CI\] = 1.07 \[0.99, 1.15\], *p* = 0.0729 after). In the recent analysis from the DIAGRAM Consortium, rs231362 near *KCNQ1* was identified to be associated with type 2 diabetes. This signal is independent of the original signal identified in the Japanese population as revealed by conditional analysis. Consistent with the evidence observed for *KCNQ1*, our finding highlighted that multiple common genetic variations within the same gene region may independently contribute to disease risk \[[@CR6], [@CR12]\]. It will be worthwhile undertaking a further investigation of this region to search for population-specific and/or disease causal variants in different ethnic groups by fine-mapping as well as transethnic mapping.

The other genes in the region of our identified variant are also potential candidate genes for diabetes. *ARF5* belongs to a family of guanine nucleotide-binding proteins that have been shown to play a role in vesicular trafficking and as activators of phospholipase D \[[@CR46]\]. Islet expression of *ARF5* was found to be induced threefold in rats receiving a high-carbohydrate diet \[[@CR47]\]. The nearby *SND1* gene, also known as the p100 transcription co-activator, is a member of the micronuclease family and plays a key role in transcription and splicing. The p100 transcriptional co-activator is present in endocrine cells and tissues, including the pancreas of cattle \[[@CR48]\].

Among the type 2 diabetes loci first identified in non-European populations, other than *KCNQ1*, few have consistently been found to show a significant association in studies of individuals of European descent \[[@CR6], [@CR14], [@CR15], [@CR42]\]. The diabetes gene variant we identified, rs10229583, also showed a significant association in Europeans in the DIAGRAM Consortium, with a smaller effect size compared with East Asian individuals (*p* = 0.0024 by Cochran's *Q* statistics, *I*^2^ = 0.8913). Interestingly, rare *PAX4* mutations were first identified in Asian MODY probands \[[@CR39], [@CR41]\], but seldom found in those of European descent \[[@CR49], [@CR50]\]. This suggests that *PAX4*, like *KCNQ1*, may be particularly relevant for the pathogenesis of type 2 diabetes in East Asians individuals. Interestingly, rs10229583 is also in strong LD with a region spanning the neighbouring *SND1* gene (Fig. [3](#Fig3){ref-type="fig"}). Further resequencing and transethnic mapping should help to identify the causal gene variant for type 2 diabetes within this region.

The novel locus we identified in Chinese individuals with type 2 diabetes has not been detected in previous GWAS performed in mainly individuals of European descent. We noted a highly significant LD variation between Chinese and European individuals in the region surrounding our identified variant. There is also significant variation in allele frequencies in Chinese compared with Europeans, as well as between Chinese and African individuals. This ethnic difference in LD pattern and risk allele frequency may lead to a differential impact in different populations and warrants further investigation by resequencing.

Our study has several limitations. The sample size of our GWAS was modest, resulting in limited power to identify genetic variants with small effect sizes. We have limited our discovery study to Southern Han Chinese, although the consistent replication seen in other East Asian population suggests that the findings may be applicable to other populations of Chinese descent.

In summary, we identify rs10229583 near *PAX4* as a novel locus for type 2 diabetes in Chinese and other populations, providing new insights into the pathogenesis of type 2 diabetes.
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